Roberto Bomprezzi to Adult
This is a "connection" page, showing publications Roberto Bomprezzi has written about Adult.
Connection Strength
0.289
-
Bomprezzi R, Chen AP, Hemond CC. Cervical spondylosis is a risk factor for localized spinal cord lesions in multiple sclerosis. Clin Neurol Neurosurg. 2020 12; 199:106311.
Score: 0.055
-
Howard LG, Bomprezzi R. Demyelinating disease and psoriasis: interferon versus dimethyl fumarate. J Neurol Sci. 2014 Aug 15; 343(1-2):230-1.
Score: 0.035
-
Bomprezzi R, Schaefer R, Reese V, Misra A, Vollmer TL, Kala M. Glatiramer acetate-specific antibody titres in patients with relapsing?/?remitting multiple sclerosis and in experimental autoimmune encephalomyelitis. Scand J Immunol. 2011 Sep; 74(3):219-226.
Score: 0.029
-
Bomprezzi R, Powers JM, Shimizu J, Tsuji S, Weinshenker BG, Wingerchuk DM. IFN?-1b may severely exacerbate Japanese opticspinal MS in neuromyelitis optica spectrum: Japanese optic-spinal MS: is it MS or neuromyelitis optica and does the answer dictate treatment? Neurology. 2011 Jul 12; 77(2):195; discussion 195-6.
Score: 0.029
-
Chansakul C, Moguel-Cobos G, Bomprezzi R. Head tremor secondary to MS resolved with rituximab. Neurol Sci. 2011 Dec; 32(6):1157-60.
Score: 0.028
-
Bomprezzi R, Postevka E, Campagnolo D, Vollmer TL. A review of cases of neuromyelitis optica. Neurologist. 2011 Mar; 17(2):98-104.
Score: 0.028
-
Chang J, Campagnolo D, Vollmer TL, Bomprezzi R. Demyelinating disease and polyvalent human papilloma virus vaccination. J Neurol Neurosurg Psychiatry. 2011 Nov; 82(11):1296-8.
Score: 0.027
-
Treaba CA, Herranz E, Barletta VT, Mehndiratta A, Sloane JA, Granberg T, Miscioscia A, Bomprezzi R, Loggia ML, Mainero C. Phenotyping in vivo chronic inflammation in multiple sclerosis by combined 11C-PBR28 MR-PET and 7T susceptibility-weighted imaging. Mult Scler. 2024 Dec; 30(14):1755-1764.
Score: 0.018
-
Bomprezzi R, Ringn?r M, Kim S, Bittner ML, Khan J, Chen Y, Elkahloun A, Yu A, Bielekova B, Meltzer PS, Martin R, McFarland HF, Trent JM. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet. 2003 Sep 01; 12(17):2191-9.
Score: 0.016
-
Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, Pandey K, Donnelly S, Pawate S, Bomprezzi R, Smith D, Kolb C, Qureshi S, Okuda D, Kalina J, Rimler Z, Green R, Monson N, Hoyt T, Bradshaw M, Fallon J, Chamot E, Bucello M, Beh S, Cutter G, Major E, Herbert J, Frohman EM. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016 Aug; 87(8):885-9.
Score: 0.010
-
Sun F, Ladha SS, Yang L, Liu Q, Shi SX, Su N, Bomprezzi R, Shi FD. Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis. Muscle Nerve. 2014 Apr; 49(4):487-94.
Score: 0.009
-
Annibali V, Di Giovanni S, Cannoni S, Giugni E, Bomprezzi R, Mattei C, Elkahloun A, Coccia EM, Alf? M, Orzi F, Ristori G, Salvetti M. Gene expression profiles reveal homeostatic dynamics during interferon-beta therapy in multiple sclerosis. Autoimmunity. 2007 Feb; 40(1):16-22.
Score: 0.005